ketanserin has been researched along with Heart Defects, Congenital in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quero Jiménez, MC | 1 |
| Burgueros Valero, M | 1 |
| González Dieguez, C | 1 |
| Domínguez Pérez, F | 1 |
| Pinto Corraliza, J | 1 |
| Rodríguez Fernández, M | 1 |
1 review available for ketanserin and Heart Defects, Congenital
| Article | Year |
|---|---|
[Management of pulmonary circulation alterations].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 1993 |